Gilead exercises option for Kymera's cancer drug candidate KT-200
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
April 9, 2026 7:01 AM EDTKT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidateÂ
Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences
WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced that Gilead Sciences, Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue... More
